FGFR2 and gastric cancer: FGFR2 overexpression was identified in 60% of patients with GC, and FGFR2-amplification (FGFR2-amp) was found to occur in approximately 2–15% of these patients (Matsumoto et al., 2012; Su et al., 2014; Han et al., 2015; Ahn et al., 2016; Jia et al., 2016; Kim et al., 2019b).